North America to remain largest growth driver through 2024, says Leo Pharma
The North American business grew 42 percent at constant exchange rates in the first quarter of 2024.
Revenue growth in the North American market has continued into the first quarter of the year for Leo Pharma, and according to the pharmaceutical company, this trend is expected to continue for the rest of 2024.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Leo Pharma upgrades full-year guidance
For subscribers
